Quantcast

Latest Bacillus anthracis Stories

dc1e4d9185549e3970a36206cb85ec7b
2009-09-05 12:28:22

Researchers at Albert Einstein College of Medicine of Yeshiva University have identified two small protein fragments  that could be developed into an anthrax vaccine that may cause fewer side effects than the current vaccine. The research is significant because anthrax is considered a major bioterrorism threat. The current anthrax vaccine is intended mainly for members of the armed forces serving in areas considered high risk and for individuals involved in homeland biosecurity. "Our...

2009-09-03 07:54:00

ANNAPOLIS, Md., Sept. 3 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program were presented at the Bacillus - ACT 2009 meeting, August 30 - September 3, 2009, organized by the American Society for Microbiology. David...

2009-08-20 15:36:13

Research published by Army scientists indicates that a minor reduction in levels of one particular gene, known as CD45, can provide protection against two divergent microbes: the virus that causes Ebola hemorrhagic fever and the bacterium that causes anthrax. Taken together, the results suggest a common host restriction factor and a promising approach to drug development for treating two completely different infections.Writing in the August 20 online issue of Cell Host and Microbe, scientists...

2009-07-09 06:00:00

ROCKVILLE, Md., July 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced publication by The New England Journal of Medicine of the results of two pivotal animal efficacy studies, which showed the life-saving potential of the Company's human monoclonal antibody drug raxibacumab (ABthrax(TM)), as well as the results of human safety studies, which supported the use of raxibacumab in the event of life-threatening inhalation anthrax disease. (Logo:...

2009-06-02 07:30:00

ANNAPOLIS, Md., June 2 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) in response to a Broad Agency Announcement (BAA-BARDA-09-34) for advanced research and development of medical countermeasures for chemical, biological, radiological and nuclear threats....

2009-03-31 08:00:00

ANNAPOLIS, Md., March 31 /PRNewswire-FirstCall/ --PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new mechanism of action data for Valortim(R) were presented at the Keystone Symposia on Molecular and Cellular Biology Conference on Dendritic Cells, March 29-April 3, 2009 in Banff, Alberta. The data were presented by Dr. Alan S. Cross, Professor of Medicine and Dr. Subhendu Basu,...

df1f117d5ec266e963a6d3607ff3e1291
2009-03-16 08:35:00

Scientists are suggesting that the deadly bacteria anthrax has ancient links to North America. Anthrax was widely publicized during the attacks of 2001, in which envelopes laced with the deadly bacteria were linked to the deaths of five people. Since those attacks, US agencies have spent more than $50 billion on defenses against biological warfare although no new anthrax attacks have been reported. The bacteria's effects are more commonly seen among grazing animals. According to USA Today,...

2009-02-24 08:00:00

ANNAPOLIS, Md., Feb. 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a Phase II study of SparVax(TM) and pharmacokinetic (PK) data for Valortim(R) were presented at the 7th Annual ASM Biodefense and Emerging Diseases Research Meeting, being held in Baltimore, MD, February 22-25, 2009. David P. Wright, President and Chief Executive...

2008-10-28 09:00:07

PRINCETON, N.J. and ANNAPOLIS, Md., Oct. 28 /PRNewswire-FirstCall/ -- Medarex, Inc. , a leading monoclonal antibody company, and PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, today announced results from a pilot study showing that the anthrax anti-toxin, Valortim(R) (MDX-1303), enhanced survival as compared to a control group in a therapeutic animal model known as the New Zealand White (NZW) rabbit model. Valortim is a...

d9cba98a0079fb0777504cd1be9b50351
2008-08-02 13:46:21

Americans became fearful of anthrax in October of 2001, after the white powder killed five people and sickened 17 as it was sent in envelopes through the U.S. postal service. The deadly attacks created contamination scares throughout the country and forced the post office to alter its letter-handling procedures. The tragedy is now back in the news with the apparent suicide of biodefense researcher Bruce E. Ivins of the government labs at Fort Detrick, Maryland. At the time of his death,...


Latest Bacillus anthracis Reference Libraries

11_ca5cd45b16f3d4936fde0520fef6557b
2011-04-14 14:43:25

Bacillus anthracis is a Gram-positive spore-forming, rod-shaped bacterium, with a width of 1-1.2µm and a length of 3-5µm. It can grow in aerobic or anaerobic conditions. It is the only known bacterium to synthesize a protein capsule and the only pathogenic bacterium to carry its own adenylyl cyclase virulence factor. They form oval spores located centrally in a non-swollen sporangium. These spores are highly resilient and can survive extreme temperatures, low-nutrient environments, and...

More Articles (1 articles) »
Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related